Symbiotec Pharmalab IPO last GMP is ₹240, last updated August 31 2026 09:18 am. With the upper price band of ₹988, Symbiotec Pharmalab IPO’s Estimated listing Price is ₹1228 (cap price + today’s GMP). Tha expected percentage gain/loss per share is 24.29%
We update the GMP daily. Based on grey market activity over the last 13 session, the IPO’s GMP is trending upward today, indicating expectations of a strong listing. During this period, the GMP ranged from a low of ₹220 to a high of ₹410 . stay with us for the latest Symbiotec Pharmalab IPO GMP updates, daily price trends, and expected listing price.
| GMP Date | IPO Price | GMP | EST. Listing Price | EST. Profit* | Last Updated |
|---|---|---|---|---|---|
| 31-08-2026 | ₹988 | ₹240 | ₹1228(24.29%) | ₹3,600 | 09:18 |
| 30-08-2026 | ₹988 | ₹240 | ₹1228(24.29%) | ₹3,600 | 08:34 |
| 29-08-2026 | ₹988 | ₹260 | ₹1248(26.32%) | ₹3,900 | 09:33 |
| 28-08-2027 | ₹988 | ₹270 | ₹1258(27.33%) | ₹4,050 | 14:17 |
| 27-08-2026 | ₹988 | ₹260 | ₹1248(26.32%) | ₹3,900 | 15:27 |
| 26-08-2026 | ₹988 | ₹350 | ₹1338(35.43%) | ₹5,250 | 11:17 |
| 25-08-2026 | ₹988 | ₹340 | ₹1328(34.41%) | ₹5,100 | 09:22 |
| 24-08-2026 | ₹988 | ₹395 | ₹1383(39.98%) | ₹5,925 | 14:51 |
| 23-08-2026 | ₹988 | ₹410 | ₹1398(41.50%) | ₹6,150 | 09:21 |
| 22-08-2026 | ₹988 | ₹410 | ₹1398(41.50%) | ₹6,150 | 15:10 |
| 21-08-2026 | ₹988 | ₹345 | ₹1333(34.92%) | ₹5,175 | 15:25 |
| 20-08-2026 | ₹988 | ₹300 | ₹1288(30.36%) | ₹4,500 | 14:24 |
| 19-08-2026 | ₹988 | ₹220 | ₹1208(22.27%) | ₹3,300 | 13:55 |
Symbiotec Pharmalab IPO Dates
The Symbiotec Pharmalab IPO Open date is August 24 and the close date is August 27. The Symbiotec Pharmalab IPO allotment will be finalized on August 28 and the IPO listing on September 1.
| IPO Open Date: | 24-08-2026 |
| IPO Close Date: | 27-08-2026 |
| Basis of allotment: | 28-08-2026 |
| Refunds: | 31-08-2026 |
| Credit to Demat Account: | 31-08-2026 |
| IPO Listing Date: | 01-09-2026 |
Company Overview
Symbiotec Pharmalab Limited is a research-driven pharmaceutical company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs), complex steroid compounds, and niche pharmaceutical products for global healthcare markets. Established in 2002 and headquartered in Indore, Madhya Pradesh, the company serves customers across regulated and semi-regulated markets through its advanced manufacturing facilities and strong research capabilities .
Over the years, Symbiotec has built expertise in fermentation technologies, steroid-based APIs, and specialty pharmaceutical ingredients, enabling it to cater to a diverse range of pharmaceutical and biotechnology companies worldwide. The company focuses on quality, regulatory compliance, innovation, and long-term customer relationships, supported by its manufacturing network and international presence through subsidiaries and strategic operations.
With a growing global footprint and a focus on high-value pharmaceutical solutions, Symbiotec Pharmalab aims to strengthen its position in the pharmaceutical supply chain while expanding its product portfolio and production capabilities to support future growth.